Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancer

Estrogen drives both transcriptional activation and proteolysis of estrogen receptor α (ERα; encoded by ESR1). Here we observed variable and overlapping ESR1 mRNA levels in 200 ERα-negative and 50 ERα-positive primary breast cancers examined, which suggests important posttranscriptional ERα regulation. Our results indicate that Src cooperates with estrogen to activate ERα proteolysis. Inducible Src stimulated ligand-activated ERα transcriptional activity and reduced ERα t1/2. Src and ERα levels were inversely correlated in primary breast cancers. ERα-negative primary breast cancers and cell lines showed increased Src levels and/or activity compared with ERα-positive cancers and cells. ERα t1/2 was reduced in ERα-negative cell lines. In both ERα-positive and -negative cell lines, both proteasome and Src inhibitors increased ERα levels. Src inhibition impaired ligand-activated ERα ubiquitylation and increased ERα levels. Src siRNA impaired ligand-activated ERα loss in BT-20 cells. Pretreatment with Src increased ERα ubiquitylation and degradation in vitro. These findings provide what we believe to be a novel link between Src activation and ERα proteolysis and support a model whereby crosstalk between liganded ERα and Src drives ERα transcriptional activity and targets ERα for ubiquitin-dependent proteolysis. Oncogenic Src activation may promote not only proliferation, but also estrogen-activated ERα loss in a subset of ERα-negative breast cancers, altering prognosis and response to therapy.

[1]  S. Nakashima,et al.  MDM2 Enhances the Function of Estrogen Receptor α in Human Breast Cancer Cells , 2001 .

[2]  A. Harris,et al.  Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  J. Polman,et al.  ERβ: Identification and characterization of a novel human estrogen receptor , 1996 .

[4]  Y. Miyoshi,et al.  Quantitative analysis of estrogen receptor‐α and ‐β messenger RNA expression in breast carcinoma by real‐time polymerase chain reaction , 2000 .

[5]  P. Chambon,et al.  Cloning of the human oestrogen receptor cDNA. , 1986, Journal of steroid biochemistry.

[6]  A. Caudy,et al.  Regulation of Transcriptional Activation Domain Function by Ubiquitin , 2001, Science.

[7]  J. Blenis,et al.  pp90rsk1 Regulates Estrogen Receptor-Mediated Transcription through Phosphorylation of Ser-167 , 1998, Molecular and Cellular Biology.

[8]  B. Katzenellenbogen,et al.  Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. , 1996, Molecular endocrinology.

[9]  N. Webster,et al.  The human estrogen receptor has two independent nonacidic transcriptional activation functions , 1989, Cell.

[10]  R. Weigel,et al.  Analysis of estrogen receptor messenger RNA in breast carcinomas from archival specimens is predictive of tumor biology. , 1997, The American journal of pathology.

[11]  R. Thampan,et al.  Ubiquitination of the rat uterine estrogen receptor: dependence on estradiol. , 1995, Biochemical and biophysical research communications.

[12]  S. F. Arnold,et al.  In vivo and in vitro phosphorylation of the human estrogen receptor , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[13]  P. Chambon,et al.  Differential ligand‐dependent interactions between the AF‐2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. , 1996, The EMBO journal.

[14]  M. Erdos,et al.  BRCA1 inhibition of estrogen receptor signaling in transfected cells. , 1999, Science.

[15]  D. Slamon,et al.  Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy , 2004, Breast Cancer Research and Treatment.

[16]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.

[17]  F. Kern,et al.  Hyperactivation of MAPK Induces Loss of ERα Expression in Breast Cancer Cells , 2001 .

[18]  W. Shao,et al.  Coactivator AIB1 links estrogen receptor transcriptional activity and stability. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. , 1993, Molecular endocrinology.

[20]  E. Alarid,et al.  Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. , 1999, Molecular endocrinology.

[21]  J. Lees,et al.  Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. , 1992, The EMBO journal.

[22]  F. Stossi,et al.  Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. , 2006, Molecular endocrinology.

[23]  P. Cohen,et al.  Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. , 1986, The Journal of biological chemistry.

[24]  B. O’Malley,et al.  Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor-regulated transcription? , 2004, Molecular endocrinology.

[25]  J. Gustafsson,et al.  Estrogen receptor transcription and transactivation: Basic aspects of estrogen action , 2000, Breast Cancer Research.

[26]  Carsten O. Peterson,et al.  Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. , 2001, Cancer research.

[27]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  K. Korach,et al.  Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Christopher J. Barnes,et al.  The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor α to the plasma membrane , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[30]  B. O’Malley,et al.  The 26S Proteasome Is Required for Estrogen Receptor-α and Coactivator Turnover and for Efficient Estrogen Receptor-α Transactivation , 2000 .

[31]  A. Ferguson,et al.  Regulation of Estrogen Receptor α Function in Breast Cancer , 1997 .

[32]  A. Bilancio,et al.  Steroid‐induced androgen receptor–oestradiol receptor β–Src complex triggers prostate cancer cell proliferation , 2000, The EMBO journal.

[33]  Diego Sisci,et al.  Fibronectin and type IV collagen activate ERα AF-1 by c-Src pathway: effect on breast cancer cell motility , 2004, Oncogene.

[34]  E. Diamandis,et al.  Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. , 1993, Oncogene.

[35]  M. Tsai,et al.  The Angelman Syndrome-Associated Protein, E6-AP, Is a Coactivator for the Nuclear Hormone Receptor Superfamily , 1999, Molecular and Cellular Biology.

[36]  D. Vorojeikina,et al.  Estradiol-binding mechanism and binding capacity of the human estrogen receptor is regulated by tyrosine phosphorylation. , 1997, Molecular endocrinology.

[37]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[38]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[39]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. McDonnell,et al.  The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators* , 2001, The Journal of Biological Chemistry.

[41]  J. Ellenberg,et al.  Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. , 2003, Molecular cell.

[42]  W. Tansey,et al.  Transcriptional activation: risky business. , 2001, Genes & development.

[43]  K. Ley,et al.  Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase , 2000, Nature.

[44]  Zhiyong Guo,et al.  Regulation of androgen receptor activity by tyrosine phosphorylation. , 2006, Cancer cell.

[45]  Yiling Lu,et al.  Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma* , 2005, Molecular & Cellular Proteomics.

[46]  S. Cl,et al.  Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors. , 2001 .

[47]  V. Jordan,et al.  “Studies on the estrogen receptor in breast cancer” — 20 years as a target for the treatment and prevention of cancer , 2004, Breast Cancer Research and Treatment.

[48]  B. O’Malley,et al.  Proteasome-dependent degradation of the human estrogen receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[49]  S. Lehrer,et al.  A variant estrogen receptor messenger ribonucleic acid is associated with reduced levels of estrogen binding in human mammary tumors. , 1988, Molecular endocrinology.

[50]  K. Korach,et al.  The Multifaceted Mechanisms of Estradiol and Estrogen Receptor Signaling* , 2001, The Journal of Biological Chemistry.

[51]  Chi-Wai Wong,et al.  Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[52]  A. Bilancio,et al.  PI3‐kinase in concert with Src promotes the S‐phase entry of oestradiol‐stimulated MCF‐7 cells , 2001, The EMBO journal.

[53]  M. Maa,et al.  c-Src-mediated Phosphorylation of the Epidermal Growth Factor Receptor on Tyr845 and Tyr1101 Is Associated with Modulation of Receptor Function* , 1999, The Journal of Biological Chemistry.

[54]  Myles Brown,et al.  Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription , 2000, Cell.

[55]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[56]  B. Rowan,et al.  The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity. , 2005, Molecular endocrinology.

[57]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[58]  P. Bontempo,et al.  Tyrosine kinase/p21ras/MAP‐kinase pathway activation by estradiol‐receptor complex in MCF‐7 cells. , 1996, The EMBO journal.

[59]  E. Alarid,et al.  Thyroid hormone is an inhibitor of estrogen-induced degradation of estrogen receptor-alpha protein: estrogen-dependent proteolysis is not essential for receptor transactivation function in the pituitary. , 2003, Endocrinology.

[60]  K. Nephew,et al.  Inhibiting Proteasomal Proteolysis Sustains Estrogen Receptor-α Activation , 2004 .

[61]  C. Klinge,et al.  Estrogen receptor interaction with co-activators and co-repressors☆ , 2000, Steroids.

[62]  K. Miyazono,et al.  Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins. , 2001, Molecular biology of the cell.

[63]  D. Picard,et al.  Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. , 1996, The EMBO journal.

[64]  N. Roodi,et al.  Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. , 1995, Journal of the National Cancer Institute.

[65]  J. Slingerland,et al.  Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Sheila M. Thomas,et al.  Cellular functions regulated by Src family kinases. , 1997, Annual review of cell and developmental biology.

[67]  D. Vorojeikina,et al.  Function of estrogen receptor tyrosine 537 in hormone binding, DNA binding, and transactivation. , 1999, Biochemistry.

[68]  R. Spang,et al.  Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[69]  S. Parsons,et al.  Src family kinases and HER2 interactions in human breast cancer cell growth and survival , 2001, Oncogene.

[70]  Heung-Chin Cheng,et al.  Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530 , 1999, Oncogene.